相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials
Alessandro Rizzo et al.
EUROPEAN UROLOGY FOCUS (2022)
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
Matteo Santoni et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni et al.
DIAGNOSTICS (2021)
Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy
Matteo Santoni et al.
EUROPEAN UROLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review
Alessandro Rizzo et al.
FUTURE ONCOLOGY (2021)
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news
Francisco Zambrana et al.
CANCER TREATMENT REVIEWS (2021)
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
Francesco Massari et al.
EUROPEAN JOURNAL OF CANCER (2021)
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States
Matteo Santoni et al.
CLINICAL GENITOURINARY CANCER (2021)
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni et al.
CANCERS (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
Daniele Santini et al.
ONCOTARGET (2016)
Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
Matteo Santoni et al.
JOURNAL OF UROLOGY (2015)
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside
Matteo Santoni et al.
CANCER AND METASTASIS REVIEWS (2014)
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials
Roberto Iacovelli et al.
CANCER TREATMENT REVIEWS (2014)
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
D. Y. Heng et al.
ANNALS OF ONCOLOGY (2012)
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science
Camillo Porta et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)